The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Open accessAbstract
Amyloid plaques and neurofibrillary tangles (NFTs) are the pathological hallmarks of Alzheimer disease (AD). There is controversy regarding the use of current diagnostic criteria for AD and whether amyloid plaques and NFTs contribute to cognitive impairment. Because AD is specific to humans, rigorous and comprehensiveclinicopathologic studies are necessary to test and refine hypotheses of AD diagnosis and pathogenesis. Neither the clinical nor the pathological aspects of AD evolve in a linear manner, but thepredictable sequence of AD pathology allows for stage-based correlations with cognitive deterioration. We discuss subsets of patients with clinical dementia who lack amyloid plaques and NFTs and, conversely, whether individuals without antemortem cognitive impairment can harbor severe AD-type pathological findings at autopsy. There are many medical, technical, and anatomical challenges to clinicopathologic studies in AD. For example, at least two thirds of persons older than 80 years have non-AD brain diseases that can effect on cognitive function. We argue that existing data strongly support the hypothesis that both amyloid plaques and NFTs contribute to cognitive impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinically, AD is characterized by several features, notably a progressive cognitive decline involving loss of memory and higher executive functioning1.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Evaluation of AD status was conducted by the AD Center Neuropathology and Clinical Cores using guidelines set forth by the National Institute on Aging Reagan Institute that included evaluation of neurofibrillary tangles and neuritic senile plaques [36–38].”
From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, the first pathological insults to neurons in AD and aMCI occur at pre- and post-synaptic membranes1,3.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measured
In the citing paper
“Indeed, this is precisely the observation reported by one of the largest autopsy series to date (142) and is well supported by AD biomarker studies (143-145).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“It is important to emphasize that, among thousands of cases from dozens of CPC studies worldwide, there never has been a report of a thoroughly documented individual with truly “end-stage” neocortical NFT pathology who lacked antemortem cognitive impairment proximal to death (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“However, not all Braak stage VI brains were the same; there was significant variation in NFT burden in these cases (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“There have been many clinicopathological studies that have correlated amyloid plaques with cognitive deficits in AD, with an emerging picture that the strongest correlation exists in the earliest stages of the disease and this association greatly weakens as NFTs and neocortical degeneration become more widespread [9, 102, 103, 157, 160, 169].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationLOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS
Scoville, W. B., & Milner, B. (1957) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.20.1.11 · Cited by 7,322
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Research works printed but not linked: 1
- Centers for Disease Control and Prevention. Prevalence of stroke-United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:469–74
Cited by
Sorted by citations
Items 401–500 of 638
Identification of β-amyloid species in canine cerebrospinal fluid by mass spectrometry
Sarasa, L., Allué, J. A., Pesini, P., González‐Martínez, Á., & Sarasa, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.009 · Cited by 14
Initiative, A. D. N., Mukherjee, S., Trittschuh, E. H., Gibbons, L. E., Mackin, R. S., Saykin, A. J., & Crane, P. K. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9207-y · Cited by 14
Antemortem Prediction of Braak Stage
Carlson, J. O. E., Gatz, M., Pedersen, N. L., Graff, C., Nennesmo, I., Lindström, A.-K., & Gerritsen, L. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000251 · Cited by 14
Webster, J. M., Yang, Y.-T., Miller, A. T., Zane, A., Scholz, K., Stone, W. J., Mudium, N., Corbin-Stein, N. J., Won, W.-J., Stoll, A. C., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107323 · Cited by 13
Torrealba, E., Aguilar-Zerpa, N., Garcia-Morales, P., & Díaz, M. L. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220116 · Cited by 15
Therapeutic Potential of P110 Peptide: New Insights into Treatment of Alzheimer’s Disease
Srivastava, A., Johnson, M., Renna, H. A., Sheehan, K. M., Ahmed, S., Palaia, T. A., Pinkhasov, A., Gomolin, I. H., Leon, J. D., & Reiss, A. B. (2023) · Life · doi:10.3390/life13112156 · Cited by 13
Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer’s disease
Nehra, G., Maloney, B. J., Smith, R. R., Chumboatong, W., Abner, E. L., Nelson, P. T., Bauer, B., & Hartz, A. M. S. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00615-8 · Cited by 13
Self-citationMorito, T., Qi, M., Kamano, N., Sasaguri, H., Bez, S., Foiani, M. S., Duff, K., Benner, S., Endo, T., Hama, H., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101024 · Cited by 14
Fornicola, W., Pelcovits, A., Li, B.-X., Heath, J., Perry, G. L., & Castellani, R. J. (2014) · The Open Neurology Journal · doi:10.2174/1874205x01408010022 · Cited by 14
Butterfield, D. A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.035 · Cited by 13
Xu, W., Bai, A., Liang, Y., & Lin, Z. (2024) · Gerontology · doi:10.1159/000535082 · Cited by 12
Wang, W., Myers, S. J., Ollen‐Bittle, N., & Whitehead, S. N. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106798 · Cited by 12
Comparison of Methods of Detecting IL-1β in the Blood of Alzheimer’s Disease Subjects
Remnitz, A. D., Hadad, R., Keane, R. W., Dietrich, W. D., & Vaccari, J. P. D. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020831 · Cited by 13
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 14
The Potential Neuroprotective Effects of Extracts from Oat Seedlings against Alzheimer’s Disease
Lee, W. S., Lee, H., Yang, J. Y., Shin, H.-L., Choi, S., Kim, J.-K., Seo, W. D., & Kim, E. H. (2022) · Nutrients · doi:10.3390/nu14194103 · Cited by 12
Mullane, K., & Williams, M. J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.004 · Cited by 13
The potential link between the development of Alzheimer’s disease and osteoporosis
Nasme, F., Behera, J., Tyagi, P., Debnath, N., Falcone, J. C., & Tyagi, N. (2025) · Biogerontology · doi:10.1007/s10522-024-10181-z · Cited by 12
Protocol Report on the Transcranial Photobiomodulation for Alzheimer’s Disease (TRAP-AD) Study
Iosifescu, D. V., Song, X., Gersten, M. B., Adib, A., Cho, Y., Collins, K. A., Yates, K. F., Puerto, A. M. H., McEachern, K. M., Osorio, R. S., et al. (2023) · Healthcare · doi:10.3390/healthcare11142017 · Cited by 11
Microglial responses partially mediate the effect of Aβ on cognition in Alzheimer's disease
Madsen, L. S., Ismail, R., Parbo, P., Kjeldsen, P. L., Schaldemose, J. L., Hansen, K. V., Gottrup, H., Aanerud, J., Eskildsen, S. F., & Brooks, D. J. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14298 · Cited by 13
Cuadrado‐Tejedor, M., Pérez-González, M., Alfaro‐Ruiz, R., Badesso, S., Sucunza, D., Espelosin, M., Ursúa, S., Lachén‐Montes, M., Fernández‐Irigoyen, J., Santamaría, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111950 · Cited by 11
The neuropathological landscape of Hispanic and non-Hispanic White decedents with Alzheimer disease
Scalco, R., Saito, N. H., Beckett, L. A., Nguyen, M.-L., Huie, E. Z., Wang, H.-P., Flaherty, D., Honig, L. S., DeCarli, C. S., Rissman, R. A., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01574-1 · Cited by 11
Akkaya, U. M., & Kalkan, H. (2023) · Biomolecules · doi:10.3390/biom13111563 · Cited by 11
Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
Lai, S., Zhang, M., Xu, D., Zhang, Y., Qiu, L., Tian, C., & Zheng, J. C. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0028-y · Cited by 11
Cohen, A., Ardern, C. I., & Baker, J. R. (2017) · Public Health · doi:10.1016/j.puhe.2017.06.019 · Cited by 12
Giil, L. M., Aarsland, D., Hellton, K. H., Lund, A., Heidecke, H., Schulze‐Forster, K., Riemekasten, G., Vik‐Mo, A. O., Kristoffersen, E. K., Vedeler, C. A., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170882 · Cited by 11
Bifunctional Copper Chelators Capable of Reducing Aβ Aggregation and Aβ-Induced Oxidative Stress
Krasnovskaya, O. O., Abramchuk, D., Vaneev, A. N., Gorelkin, P. V., Abakumov, M. A., Timoshenko, R. V., Kuzmichev, I., Chmelyuk, N. S., Vadekhina, V. V., Kuanaeva, R. M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c03152 · Cited by 10
Sun, K. T., & Mok, S. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00512 · Cited by 12
Balancing Microglial Density and Activation in Central Nervous System Development and Disease
Wang, S., Pan, L., Sun, C., Ma, C., & Pan, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050344 · Cited by 11
Unlocking the cellular mystery: how proton pump inhibitors may alter the dementia landscape
Mohan, M., Mannan, A., Singh, S., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149702 · Cited by 12
Microcurrent therapy as the nonpharmacological new protocol against Alzheimer’s disease
Kim, E. H., Lee, W. S., Lee, J. H., & Kwon, D. R. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1344072 · Cited by 10
Accelerating Alzheimer’s pathogenesis by GRK5 deficiency via cholinergic dysfunction
Suo, W. Z. (2013) · Advances in Alzheimer s Disease · doi:10.4236/aad.2013.24020 · Cited by 10
FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells
Ye, X., Tai, W., Bao, X., Chen, X., & Zhang, D. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0918-4 · Cited by 10
Dieter, L. S., & Estus, S. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-34 · Cited by 12
Scuderi, C., & Golini, L. (2021) · Animals · doi:10.3390/ani11092584 · Cited by 14
Sur, C., Adamczuk, K., Scott, D., Kost, J. T., Sampat, M. P., Buckley, C. J., Farrar, G., Newton, B., Suhy, J., Bennacef, I., et al. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01735-z · Cited by 10
Supramolecular organizing centers at the interface of inflammation and neurodegeneration
Sušjan, P., Ramuta, T. Ž., Boršić, E., Orehek, S., & Hafner‐Bratkovič, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940969 · Cited by 11
Neocortical β‐amyloid area is associated with dementia and APOE in the oldest‐old
Berlau, D. J., Corrada, M. M., Robinson, J. L., Geser, F., Arnold, S. E., Lee, V. M. ‐., Kawas, C. H., & Trojanowski, J. Q. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.011 · Cited by 11
Nutrients in Alzheimer’s Disease: The Interaction of Diet, Drugs and Disease
Liyanage, S. I., Vilekar, P., & Weaver, D. F. (2019) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2018.353 · Cited by 11
APOE in Alzheimer's disease and neurodegeneration
Butterfield, D. A., & Johnson, L. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104847 · Cited by 10
Braak, H., & Tredici, K. D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374105-9.00269-0 · Cited by 10
Self-citationAretz, B., Doblhammer, G., & Heneka, M. T. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14320 · Cited by 9
Neurobiological effects of music-making interventions for older adults: a systematic review
Espinosa, N., Schrire, Z. M., McKinnon, A. C., Almgren, H., Mowszowski, L., & Naismith, S. L. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03006-7 · Cited by 9
Giil, L. M., Aarsland, D., & Vik‐Mo, A. O. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12152 · Cited by 11
Wang, J., Xu, X., Wang, C., Ye, D., Chen, R., Peng, P., Huang, H., Yan, Y., Chen, Y., Wang, S., et al. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2279647 · Cited by 9
Gantenerumab for early Alzheimer’s disease: a systematic review and meta-analysis
de Almeida, A. M., Leite, M. G. H. S. J., Lopes, L. M., Lima, P. L. G., Barros, M. L. S., Pinheiro, S. L. R., Andrade, Í. B., Viana, P., Morbach, V., Marinheiro, G., et al. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2367016 · Cited by 10
Cognitive reserve: the evolution of the conceptual framework
Serra, L., Caltagirone, C., & Bozzali, M. (2017) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000159 · Cited by 9
Amirpour, M., Mirshekar, M. A., Sedaghat, G., Montazerifar, F., Shourestani, S., Arabmoazzen, S., & Naghizadeh, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.2003946 · Cited by 9
Pathophysiology of the choroid plexus in brain diseases
Mihaljević, S., Michalicová, A., Bhide, M., & Kováč, A. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021032 · Cited by 9
Wasp Venom Ameliorates Scopolamine-Induced Learning and Memory Impairment in Mice
Chae, J. H., Oh, J., Lim, J. S., Jeong, Y. A., Yun, H. S., Jang, C. H., Kim, H. J., & Kim, J. (2022) · Toxins · doi:10.3390/toxins14040256 · Cited by 9
Wolters, E. E., Ossenkoppele, R., Golla, S. S. V., Verfaillie, S. C. J., Timmers, T., Visser, D., Tuncel, H., Coomans, E. M., Windhorst, A. D., Scheltens, P., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102113 · Cited by 10
Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration
Kim, H., Lee, T., Choi, J. K., & Jeong, Y. (2020) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000422 · Cited by 9
Wang, Y., Thinakaran, G., & Kar, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098057 · Cited by 9
Medial Amygdalar Tau Is Associated With Mood Symptoms in Preclinical Alzheimer’s Disease
Li, J. S., Tun, S. M., Ficek, B., Xu, W., Wang, S., Horien, C. L., Toyonaga, T., Nuli, S. S., Zeiss, C. J., Powers, A. R., et al. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.07.012 · Cited by 8
Kaur, S., Verma, H., Dhiman, M., & Mantha, A. K. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101947 · Cited by 8
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Direct Modulation of the Gut Microbiota as a Therapeutic Approach for Alzheimer’s Disease
Wang, Y., & Dykes, G. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210806165751 · Cited by 8
GRK5 Deficiency Causes Mild Cognitive Impairment due to Alzheimer’s Disease
Suo, W. Z. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215379 · Cited by 8
Neurodegeneration, Mitochondria, and Antibiotics
Suarez-Rivero, J. M., López‐Pérez, J., Muela‐Zarzuela, I., Pastor‐Maldonado, C. J., Cilleros-Holgado, P., Gómez-Fernández, D., Álvarez-Córdoba, M., Munuera-Cabeza, M., Talaverón-Rey, M., Povea-Cabello, S., et al. (2023) · Metabolites · doi:10.3390/metabo13030416 · Cited by 9
Melatonin-mediated calcineurin inactivation attenuates amyloid beta-induced apoptosis
Hong, J.-M., Munna, A. N., Moon, J.-H., Seol, J., & Park, S. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.02.001 · Cited by 8
Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis
Park, S., & Kim, Y. S. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00201-z · Cited by 8
Mitochondrial Function in Alzheimer’s Disease: Focus on Astrocytes
Lampinen, R., Belaya, I., Boccuni, I., Malm, T., & Kanninen, K. M. (2018) · Astrocyte - Physiology and Pathology · doi:10.5772/intechopen.71825 · Cited by 8
Neuropathology of Alzheimer's Disease
Castellani, R. J., Peclovits, A., & Perry, G. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04604-9 · Cited by 8
Molecular Mechanism of Alzheimer’s Disease
Rammes, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316837 · Cited by 8
Celebrating 40 years of the University of Kentucky Alzheimer's Disease Research Center
Schmitt, F. A., Abner, E. L., Fardo, D. W., Gold, B. T., Jicha, G. A., Kryscio, R. J., Lee, D. C., Nelson, P. T., & Eldik, L. J. V. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70181 · Cited by 7
Self-citationElucidating the molecular targets in Alzheimer's disease: Advances and therapeutic implications
Soni, U., & Pujari, R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111660 · Cited by 7
Neurotransmitter Systems in Alzheimer’s Disease
Ramı́rez-Expósito, M. J., Cueto‐Ureña, C., & Martı́nez-Martos, J. M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48030334 · Cited by 7
Altered cortical thickness-based structural covariance networks in type 2 diabetes mellitus
Huang, Y., Zhang, X., Cheng, M., Yang, Z., Liu, W., Ai, K., Tang, M., Zhang, X., Lei, X., & Zhang, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1327061 · Cited by 7
Calvó‐Perxas, L., Pousa, S. L., Franch, J. V., Garriga, O. T., Blankenburg, M., Febrer, L., Flaqué, M., Vallmajó, N., Aguirregomozcorta, M., Genı́s, D., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000337340 · Cited by 7
Gholami, J., Negah, S. S., Rajabian, A., Saburi, E., & Hajali, V. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101392 · Cited by 7
Maulik, M., Thinakaran, G., & Kar, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054605 · Cited by 7
Franco, G. R. R., & Viegas, C. (2017) · Revista Virtual de Química · doi:10.21577/1984-6835.20170103 · Cited by 7
Physical activity and cognition in the elderly
Clifford, A. (2012) · Loughborough University Institutional Repository (Loughborough University) · Cited by 7
Synthesis of Anti‐Alzheimer Molecules: Bridging Chemical Approaches to Pharmaceuticals
Abbas, H., Noor, F., Khalid, S., Ahmad, M., Rasool, N., Malik, A. I., & Imran, M. (2025) · ChemistrySelect · doi:10.1002/slct.202405965 · Cited by 6
Quantification of Alzheimer disease neuropathology using tissue microarrays
Nguyen-Hao, H.-T., Liu, J., Novelli, M., Maskey, D., Schwartz, R. S., Harari, O., & Sutherland, G. T. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf064 · Cited by 6
Cortical thickness reveals sex differences in verbal and visuospatial memory
Sang, F., Zhao, S., Li, Z.-L., Yang, Y., Chen, Y., & Zhang, Z. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae067 · Cited by 7
MicroRNA Analysis in the Spinal Fluid of Alzheimer Patients: A Methodological Feasibility Study
van Harten, A. C., Mulders, J., Çevik, C., Kester, M. I., Scheltens, P., van der Flier, W. M., & Oudejans, C. B. M. (2010) · Springer eBooks · doi:10.1007/978-90-481-9382-0_37 · Cited by 6
Chen, K. T., Tesfay, R., Koran, M. E. I., Ouyang, J., Shams, S., Young, C. B., Davidzon, G., Liang, T., Khalighi, M. M., Mormino, E. C., et al. (2023) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7961 · Cited by 6
Maintaining Cognitive Health in Elderly Women
Clifford, A., Yesufu-Udechuku, A., Edwards, L., Bandelow, S., & Hogervorst, E. (2009) · Aging Health · doi:10.2217/ahe.09.65 · Cited by 7
Wang, H., Hong, X., Li, S., & Wang, Y. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0975-0 · Cited by 6
Tateishi, M., Kitajima, M., Hirai, T., Yoneda, T., Hashimoto, M., Kurehana, N., Uetani, H., Fukuhara, R., Azuma, M., & Yamashita, Y. (2018) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2017-0134 · Cited by 6
Alzheimer’s Disease: An Overview
Moreira, P. I., Zhu, X., Smith, M. A., & Perry, G. L. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00544-1 · Cited by 6
Lim, S., Kim, H., Lee, Y., & Initiative, A. D. N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329893 · Cited by 5
Puthusseri, S. P., Ravivarma, S., Johny, M., & Vengellur, A. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01187-x · Cited by 5
Dam, D. V., Valkenburg, F., Kolen, K. V., Pintelon, I., Timmermans, J., & Deyn, P. P. D. (2023) · Life · doi:10.3390/life13102088 · Cited by 5
Cardinali, C. A. E. F., Martins, Y. A., de Moraes, R. C. M., Costa, A. P., Alencar, M. B., Silber, A. M., & Torrão, A. D. S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00113 · Cited by 5
Neurodegenerative Disorders in Criminal Offending and Cognitive Decline Among Aging Inmates
Veggi, S., & Roveta, F. (2025) · NeuroSci · doi:10.3390/neurosci6010005 · Cited by 5
Sirimaharaj, N., Thiankhaw, K., Chattipakorn, N., & Chattipakorn, S. C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04904-7 · Cited by 5
Trompeta, C., Gasca‐Salas, C., Rodríguez‐Rojas, R., Fernández‐Rodríguez, B., Clarimón, J., García‐Cañamaque, L., Guida, P., Hernández‐Fernández, F., Sánchez‐Juan, P., Olazarán, J., et al. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123510 · Cited by 6
Hildre, A. S., Solvang, S.-E. H., Aarsland, D., Midttun, Ø., McCann, A., Ervik, A. O., Nygard, O. K., Ueland, P. M., Nordrehaug, J. E., & Giil, L. M. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146519 · Cited by 5
Malpas, C. B., Saling, M. M., Velakoulis, D., Desmond, P. M., Hicks, R. J., Zetterberg, H., Blennow, K., & O'Brien, T. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170250 · Cited by 5
Pathology of Brain Aging and Animal Models of Neurodegenerative Diseases
Youssef, S. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00066-x · Cited by 5
Ervik, A. O., Solvang, S.-E. H., Nordrehaug, J. E., Ueland, P. M., Midttun, Ø., Hildre, A. S., McCann, A., Nygard, O. K., Aarsland, D., & Giil, L. M. (2019) · International Journal of Tryptophan Research · doi:10.1177/1178646919885637 · Cited by 5
Restifo, L. L. (2021) · Genetics · doi:10.1093/genetics/iyab185 · Cited by 5
Xu, G. M., Fromholt, S., & Borchelt, D. (2022) · Biomolecules · doi:10.3390/biom12070886 · Cited by 5
Feldner, A. C., Turner, A. K., Simpson, J. F., & Estus, S. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230076 · Cited by 4
Khan, S., Hassan, M. Z., Hussain, M. S., Fatima, W., Nawaz, J., Pirih, F. N. U., Ahsan, A., Khalid, N., Qaisar, M., Eltawansy, S. A., et al. (2025) · Brain and Behavior · doi:10.1002/brb3.71125 · Cited by 4
Neuropathologic validation of the Alzheimer’s Questionnaire
Mohebpour, I., Malek‐Ahmadi, M. H., Virden, T., Breitmeyer, A. M., Sabbagh, M. N., Auman, B., Belden, C. M., Choudhury, P., Arch, A., Davis, K. J., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02222-9 · Cited by 4
Insel, P. S., Kumar, A., Hansson, O., Mattsson, N., & Initiative, A. D. N. (2023) · Neurology · doi:10.1212/wnl.0000000000207305 · Cited by 4
Eco-cognitive ageing: Post-human ecologies as enhancement technologies
Fletcher, J. R. (2023) · Gerontechnology · doi:10.4017/gt.2023.22.2.fle.08 · Cited by 4
Du, Y., Tang, S.-H., Xiao, J.-H., Wang, Y., Tian, Q., & Sun, G. (2018) · 世界针灸杂志：英文版 · doi:10.1016/j.wjam.2018.09.001 · Cited by 4
Metadata
- Authors
- Nelson, P. T., Braak, H., & Markesbery, W. R.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Kentucky (US)
- Corresponding author
- Nelson, Peter T.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 68
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- PMC
- PMC2692822
- OpenAlex
- W1985747467
- Cited by
- 643
- References
- 155
- Citations by year
- 2026: 21 · 2025: 43 · 2024: 48 · 2023: 46 · 2022: 33 · 2021: 45 · 2020: 44 · 2019: 33 · 2018: 32 · 2017: 32 · 2016: 37 · 2015: 32 · 2014: 35 · 2013: 42 · 2012: 41
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (AG028 383)
- National Institute on Aging (P30AG028383)
- National Institute of Neurological Disorders and Stroke (R01NS061933, K08NS050110)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid plaques, neurofibrillary tangles, cognitive impairment, clinicopathological correlation, Alzheimer's disease diagnosis, Alzheimer disease pathogenesis, autopsy findings
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, Neurofibrillary Tangles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
